Changing the scope of preventative and therapeutic approaches in atherothrombosis

Karlheinz Peter; Gregory Y. H. Lip

doi:10.1160/TH10-01-0063

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2010; 103(03): 487-488
DOI: 10.1160/TH10-01-0063

Theme Issue Editorial

Schattauer GmbH

Changing the scope of preventative and therapeutic approaches in atherothrombosis

Karlheinz Peter

¹Baker Heart Research Institute, Centre for Thrombosis & Myocardial Infarction, Melbourne, Victoria, Australia

,

Gregory Y. H. Lip

²Haemostasis, Thrombosis & Vascular Biology Unit, University of Birmingham Centre for Cardiovasculkar Sciences, City Hospital, Birmingham, UK

› Author Affiliations

Abstract

Full Text

References

References
1 Freudenberger RS, Schumaecker MM, Homma S. What is the appropriate approach to prevention of thromboembolism in heart failure?. Thromb Haemost 2010; 103: 489-495.
2 Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010; 103: 572-585.
3 Becker RC, Povsic T, Cohen MG. et al. Nucleic acid aptamers as antithrombotic agents opportunities in extracellular therapeutics. Thromb Haemost 2010; 103: 586-595.
4 Zürn C, Geisler T, Gawaz M. ADP-receptor blockade A case for personalised pharmacotherapy?. Thromb Haemost 2010; 103: 496-506.
5 Becker RC, Gurbel PA. Platelet P2Y₁₂ receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. Thromb Haemost 2010; 103: 535-544.
6 Brambilla M, Parolari A, Camera M. et al. Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery. Thromb Haemost 2010; 103: 516-524.
7 Henry B, Abdel Aziz M, Qibing Z. et al. Sulfated, low molecular weight lignins are potent inhibitors of plasmin in addition to thrombin and factor XA: Novel opportunity for controlling complex pathologies. Thromb Haemost 2010; 103: 507-515.
8 Charwat C, Lang I, Dettke M. et al. Effect of intramyocardial delivery of autologous bone marrow mononuclear stem cells on the regional myocardial perfusion: NOGA-guided subanalysis of the MYSTAR prospective randomised study. Thromb Haemost 2010; 103: 564-571.
9 Serebruany V, Shalito I, Kopyleva O. Prasugrel development – claims and achievements. Thromb Haemost 2009; 101: 14-22.
10 Calatzis A. Another view on prasugrel. Thromb Haemost 2009; 101: 12-13.
11 Serebruany VL. The TRITON versus PLATO trials: Differences beyond platelet inhibition. Thromb Haemost 2010; 103: 259-261.
12 Wolowacz SE, Roskell NS, Plumb JM. et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009; 101: 77-85.
13 Mueck W, Borris LC, Dahl OE. et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 453-461.
14 Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008; 99: 466-472.